COVID-19 HSE Weekly Booster Vaccination Figures

Arna fhoilsiú ag: Ordnance Survey Ireland
Catagóir: Health
Tuairimí: 9
Rátáil oscailteachta:

Please see FAQ for latest information on COVID-19 Data Hub Data Flows   https://covid-19.geohive.ie/pages/helpfaqs Category Field Label Field Display Name Explanation

ExtractDate ExtractDate Date the data is extracted

Latitude Latitude

Longitude Longitude

EpiWeek EpiWeek Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/

Week Week Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/

WeeklyBoosterVaccines Weekly Booster Vaccines Amount of boosters given during week

Vaccine Brand AstraZeneca AstraZeneca

Janssen Janssen

Moderna Moderna

Pfizer Pfizer

Additional Doses by Brand AD_AstraZeneca AdditionalDoses AstraZeneca

AD_Janssen AdditionalDoses Janssen

AD_Moderna AdditionalDoses Moderna

AD_Pfizer AdditionalDoses Pfizer

Immunocompromised Doses by Brand ID_AstraZeneca ImmunocompromisedDoses AstraZeneca

ID_Janssen ImmunocompromisedDoses Janssen

ID_Moderna ImmunocompromisedDoses Moderna

ID_Pfizer ImmunocompromisedDoses Pfizer

Gender Male Male

Female Female

Not Assigned NA

Age Group Additional Dose AD_Age0to9 AdditionalDose Age5to11 Additional Dose Age 5 to 11

AD_Age10to19 AdditionalDose Age12to19 Additional Dose Age 12 to 19

AD_Age20to29 AdditionalDose Age20to29 Additional Dose Age 20 to 29

AD_Age30to39 AdditionalDose Age30to39 Additional Dose Age 30 to 39

AD_Age40to49 AdditionalDose Age40to49 Additional Dose Age 40 to 49

AD_Age50to59 AdditionalDose Age50to59 Additional Dose Age 50 to 59

AD_Age60to69 AdditionalDose Age60to69 Additional Dose Age 60 to 69

AD_Age70to79 AdditionalDose Age70to79 Additional Dose Age 70 to 79

AD_Age80_ AdditionalDose Age80+ Additional Dose Age 80+

AD_NA AdditionalDose NotAssigned Additional Dose Not Assigned To Age Group

Age Group Additional Dose Cumulative AD_Age0to9_Cum AdditionalDose Cumulative Age5to11 Additional Dose Cumulative Age 5 to 11

AD_Age10to19_Cum AdditionalDose Cumulative Age12to19 Additional Dose Cumulative Age 12 to 19

AD_Age20to29_Cum AdditionalDose Cumulative Age20to29 Additional Dose Cumulative Age 20 to 29

AD_Age30to39_Cum AdditionalDose Cumulative Age30to39 Additional Dose Cumulative Age 30 to 39

AD_Age40to49_Cum AdditionalDose Cumulative Age40to49 Additional Dose Cumulative Age 40 to 49

AD_Age50to59_Cum AdditionalDose Cumulative Age50to59 Additional Dose Cumulative Age 50 to 59

AD_Age60to69_Cum AdditionalDose Cumulative Age60to69 Additional Dose Age 60 to 69

AD_Age70to79_Cum AdditionalDose Cumulative Age70to79 Additional Dose Age 70 to 79

AD_Age80__Cum AdditionalDose Cumulative Age80+ Additional Dose Cumulative Age 80+

AD_NA_Cum AdditionalDose Cumulative Not Assigned Additional Dose Cumulative Not Assigned To Age Group

Age Group Immunocompromised Dose ID_Age0to9 ImmunocompromisedDoses Age5to11 Immunocompromised Dose Age 5 to 11

ID_Age10to19 ImmunocompromisedDoses Age12to19 Immunocompromised Dose Age 12 to 19

ID_Age20to29 ImmunocompromisedDoses Age20to29 Immunocompromised Dose Age 20 to 29

ID_Age30to39 ImmunocompromisedDoses Age30to39 Immunocompromised Dose Age 30 to 39

ID_Age40to49 ImmunocompromisedDoses Age40to49 Immunocompromised Dose Age 40 to 49

ID_Age50to59 ImmunocompromisedDoses Age50to59 Immunocompromised Dose Age 50 to 59

ID_Age60to69 ImmunocompromisedDoses Age60to69 Immunocompromised Dose Age 60 to 69

ID_Age70to79 ImmunocompromisedDoses Age70to79 Immunocompromised Dose Age 70 to 79

ID_Age80_ ImmunocompromisedDoses Age80+ Immunocompromised Dose Age 80+

ID_NA ImmunocompromisedDoses Not Assigned Immunocompromised Dose Not Assigned To Age Group

Age Group Immunocompromised Dose Cumulative ID_Age0to9_Cum ImmunocompromisedDoses Cumulative Age5to11 Immunocompromised Dose Cumulative Age 5 to 11

ID_Age10to19_Cum ImmunocompromisedDoses Cumulative Age12to19 Immunocompromised Dose Cumulative Age 12 to 19

ID_Age20to29_Cum ImmunocompromisedDoses Cumulative Age20to29 Immunocompromised Dose Cumulative Age 20 to 29

ID_Age30to39_Cum ImmunocompromisedDoses Cumulative Age30to39 Immunocompromised Dose Cumulative Age 30 to 39

ID_Age40to49_Cum ImmunocompromisedDoses Cumulative Age40to49 Immunocompromised Dose Cumulative Age 40 to 49

ID_Age50to59_Cum ImmunocompromisedDoses Cumulative Age50to59 Immunocompromised Dose Cumulative Age 50 to 59

ID_Age60to69_Cum ImmunocompromisedDoses Cumulative Age60to69 Immunocompromised Dose Age 60 to 69

ID_Age70to79_Cum ImmunocompromisedDoses Cumulative Age70to79 Immunocompromised Dose Age 70 to 79

ID_Age80__Cum ImmunocompromisedDoses Cumulative Age80+ Immunocompromised Dose Cumulative Age 80+

ID_NA_Cum ImmunocompromisedDoses Cumulative NotAssigned Immunocompromised Dose Cumulative Not Assigned To Age Group

Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Each Age Group BoosterPer_Age0to9 IDandADTotal % of Population Age5to11 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 5 to 11

BoosterPer_Age10to19 IDandADTotal % of Population Age12to19 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 12 to 19

BoosterPer_Age20to29 IDandADTotal % of Population Age20to30 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 20 to 29

BoosterPer_Age30to39 IDandADTotal % of Population Age30to40 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 30 to 39

BoosterPer_Age40to49 IDandADTotal % of Population Age40to50 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 40 to 49

BoosterPer_Age50to59 IDandADTotal % of Population Age50to60 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 50 to 59

BoosterPer_Age60to69 IDandADTotal % of Population Age60to70 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 60 to 69

BoosterPer_Age70to79 IDandADTotal % of Population Age70to80 Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 70 to 79

BoosterPer_Age80_ IDandADTotal % of Population Age80+ Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 80+

BoosterPer_NA IDandADTotal % of Population Not Assigned Immunocompromised Dose and Additional Dose Administered As A Percentage of Population Not Assigned To Age Group

Data Resources (6)

HTML
ArcGIS Hub Dataset
ARCGIS GEOSERVICES REST API
ArcGIS GeoService

Data Resource Preview - GeoJSON

Teagmhálaí OSI
Ríomhphost Teagmhálaí customer.services@osi.ie
Uimhir Ghutháin Teagmhálaí -
Téama Sláinte
Dáta eisithe 2021-11-02
Dáta nuashonraithe 2022-08-15
Teanga English
Lamairne https://opendata-geohive.hub.arcgis.com/maps/2a4814b66d0d459cbb80dea30f61fbfe_0